Literature DB >> 24760462

De novo Stage IV breast cancer: breast conserving resection of the primary tumor?

Seema Ahsan Khan1.   

Abstract

Multiple retrospective reviews completed over the past decade suggest a survival advantage with resection of the intact primary tumor in women with metastatic breast cancer. However, these reviews are not without bias, and recently completed randomized trials do not support a significant survival benefit, although local control benefits may exist. Completion of ongoing trials is needed to reach a definitive conclusion regarding the merit of primary tumor resection for local control and survival.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  breast cancer; breast conserving surgery; local therapy; metastatic; primary tumor

Mesh:

Year:  2014        PMID: 24760462     DOI: 10.1002/jso.23621

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

1.  Perspectives of Cosmesis following Breast Conservation for Multifocal and Multicentric Breast Cancers.

Authors:  Mona P Tan; Nadya Y Sitoh; Yih-Yiow Sitoh
Journal:  Int J Breast Cancer       Date:  2015-10-04

2.  Surgery of the primary tumor improves survival in women with stage IV breast cancer in Southwest China: A retrospective analysis.

Authors:  Yuxin Xie; Xingxing Lv; Chuanxu Luo; Kejia Hu; Qiheng Gou; Keqi Xie; Hong Zheng
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

3.  Hormone receptor status may impact the survival benefit of surgery in stage iv breast cancer: a population-based study.

Authors:  Yinuo Tan; Xiaofen Li; Haiyan Chen; Yeting Hu; Mengjie Jiang; Jianfei Fu; Ying Yuan; Kefeng Ding
Journal:  Oncotarget       Date:  2016-10-25

4.  Cryoablation of Primary Breast Cancer in Patients with Metastatic Disease: Considerations Arising from a Single-Centre Data Analysis.

Authors:  Claudio Pusceddu; Luca Melis; Nicola Ballicu; Paolo Meloni; Valeria Sanna; Alberto Porcu; Alessandro Fancellu
Journal:  Biomed Res Int       Date:  2017-10-19       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.